Clinical Significance of Laboratory-determined Aspirin Poor
Responsiveness After Primary Percutaneous Coronary Intervention

J 2016

Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK et al.

Základní údaje

Originální název

Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention

Autoři

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK; Ratko LASICA; Milika ASANIN; Sanja STANKOVIC a Jelena MARINKOVIC

Vydání

CARDIOVASCULAR DRUGS AND THERAPY, DORDRECHT, SPRINGER, 2016, 0920-3206

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.820

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00100476

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Aspirin resistance; Primary PCI; Clinical outcome

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2018 15:11, Soňa Böhmová

Anotace

V originále

Aims The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI). Methods We analyzed 961 consecutive ST-elevation acute myocardial infarction patients who underwent PPCI between February 2008 and June 2011. Multiplate analyser (Dynabite, Munich, Germany) was used for the assessment of platelet reactivity. APR/AHR were defined as the upper/lower quintiles of ASPI values, determined 24 h after aspirin loading. APR patients were tailored using 300 mg maintenance dose for 30 days. The co-primary end points at 30 days were: MACE (death, non-fatal infarction, ischemia-driven target vessel revascularization and ischemic stroke) and serious bleeding according to the BARC classification. Results One hundred and 90 patients were classified as APR, and 193 patients as AHR. At admission, compared with aspirin sensitive patients (ASP), patients with APR had more frequently diabetes, anterior infarction and heart failure, while AHR patients had reduced values of creatine kinase, leukocytes, heart rate and systolic blood pressure. Compared with ASP, the rates of 30-day primary end points did not differ neither in APR group including tailored patients (MACE, adjusted OR 1.02, 95% CI 0.47-2.17; serious bleeding, adjusted OR 1.92, 95% CI 0.79-4.63), nor in patients with AHR (MACE, adjusted OR 1.58, 95% CI 0.71-5.51; serious bleeding, adjusted OR 0.69, 95% CI 0.22-2.12). Conclusions The majority of APR patients were suitable for tailoring. Neither APR including tailored patients nor AHR were associated with adverse 30-day efficacy or safety clinical outcomes.

Citovat

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK; Ratko LASICA; Milika ASANIN; Sanja STANKOVIC a Jelena MARINKOVIC. Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. CARDIOVASCULAR DRUGS AND THERAPY. DORDRECHT: SPRINGER, 2016, roč. 30, č. 2, s. 151-158. ISSN 0920-3206. Dostupné z: https://doi.org/10.1007/s10557-016-6643-8.

@article{1412152,
   author = {Mrdovic, Igor and Colic, Mirko and Savic, Lydija and Krljanac, Gordana and Kružliak, Peter and Lasica, Ratko and Asanin, Milika and Stankovic, Sanja and Marinkovic, Jelena},
   article_location = {DORDRECHT},
   article_number = {2},
   doi = {https://doi.org/10.1007/s10557-016-6643-8},
   keywords = {Aspirin resistance; Primary PCI; Clinical outcome},
   language = {eng},
   issn = {0920-3206},
   journal = {CARDIOVASCULAR DRUGS AND THERAPY},
   title = {Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention},
   volume = {30},
   year = {2016}
}

TY  - JOUR
ID  - 1412152
AU  - Mrdovic, Igor - Colic, Mirko - Savic, Lydija - Krljanac, Gordana - Kružliak, Peter - Lasica, Ratko - Asanin, Milika - Stankovic, Sanja - Marinkovic, Jelena
PY  - 2016
TI  - Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention
JF  - CARDIOVASCULAR DRUGS AND THERAPY
VL  - 30
IS  - 2
SP  - 151-158
EP  - 151-158
PB  - SPRINGER
SN  - 09203206
KW  - Aspirin resistance
KW  - Primary PCI
KW  - Clinical outcome
N2  - Aims The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI). Methods We analyzed 961 consecutive ST-elevation acute myocardial infarction patients who underwent PPCI between February 2008 and June 2011. Multiplate analyser (Dynabite, Munich, Germany) was used for the assessment of platelet reactivity. APR/AHR were defined as the upper/lower quintiles of ASPI values, determined 24 h after aspirin loading. APR patients were tailored using 300 mg maintenance dose for 30 days. The co-primary end points at 30 days were: MACE (death, non-fatal infarction, ischemia-driven target vessel revascularization and ischemic stroke) and serious bleeding according to the BARC classification. Results One hundred and 90 patients were classified as APR, and 193 patients as AHR. At admission, compared with aspirin sensitive patients (ASP), patients with APR had more frequently diabetes, anterior infarction and heart failure, while AHR patients had reduced values of creatine kinase, leukocytes, heart rate and systolic blood pressure. Compared with ASP, the rates of 30-day primary end points did not differ neither in APR group including tailored patients (MACE, adjusted OR 1.02, 95% CI 0.47-2.17; serious bleeding, adjusted OR 1.92, 95% CI 0.79-4.63), nor in patients with AHR (MACE, adjusted OR 1.58, 95% CI 0.71-5.51; serious bleeding, adjusted OR 0.69, 95% CI 0.22-2.12). Conclusions The majority of APR patients were suitable for tailoring. Neither APR including tailored patients nor AHR were associated with adverse 30-day efficacy or safety clinical outcomes.
ER  -

MRDOVIC, Igor; Mirko COLIC; Lydija SAVIC; Gordana KRLJANAC; Peter KRUŽLIAK; Ratko LASICA; Milika ASANIN; Sanja STANKOVIC a Jelena MARINKOVIC. Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. \textit{CARDIOVASCULAR DRUGS AND THERAPY}. DORDRECHT: SPRINGER, 2016, roč.~30, č.~2, s.~151-158. ISSN~0920-3206. Dostupné z: https://doi.org/10.1007/s10557-016-6643-8.

Přehled o publikaci